348 related articles for article (PubMed ID: 25794560)
21. Clonotypic analysis of immunoglobulin heavy chain sequences in patients with Waldenström's macroglobulinemia: correlation with MYD88 L265P somatic mutation status, clinical features, and outcome.
Petrikkos L; Kyrtsonis MC; Roumelioti M; Georgiou G; Efthymiou A; Tzenou T; Panayiotidis P
Biomed Res Int; 2014; 2014():809103. PubMed ID: 25197661
[TBL] [Abstract][Full Text] [Related]
22. Origin of Waldenstrom's macroglobulinaemia.
García-Sanz R; Jiménez C; Puig N; Paiva B; Gutiérrez NC; Rodríguez-Otero P; Almeida J; San Miguel J; Orfão A; González M; Pérez-Andrés M
Best Pract Res Clin Haematol; 2016 Jun; 29(2):136-147. PubMed ID: 27825459
[TBL] [Abstract][Full Text] [Related]
23. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR
Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177
[TBL] [Abstract][Full Text] [Related]
24. Current therapy guidelines for Waldenstrom's macroglobulinaemia.
Kastritis E; Dimopoulos MA
Best Pract Res Clin Haematol; 2016 Jun; 29(2):194-205. PubMed ID: 27825466
[TBL] [Abstract][Full Text] [Related]
25. A case with acute renal failure complicated by Waldenström's macroglobulinemia and cryoglobulinemia.
Yonemura K; Suzuki T; Sano K; Fujigaki Y; Ikegaya N; Hishida A
Ren Fail; 2000; 22(4):511-5. PubMed ID: 10901188
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment of cryoglobulinemic glomerulonephritis derived from Waldenström's macroglobulinemia by rituximab-CHOP and tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation.
Kawano N; Ikeda N; Yoshida S; Sugio Y; Yamashita K; Uezono S; Hayashi T; Hara S; Makino S; Shimoda K; Ueda A
Int J Hematol; 2010 Sep; 92(2):391-7. PubMed ID: 20686877
[TBL] [Abstract][Full Text] [Related]
27. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
[TBL] [Abstract][Full Text] [Related]
28. [Lymphoplasmacytic lymphoma accompanied by transformed diffuse large B-cell lymphoma with the MYD88
Kida T; Tanimura A; Ono A; Matsui T; Honma K; Fujita J; Maeda T; Shibayama H; Oritani K; Morii E; Kanakura Y
Rinsho Ketsueki; 2017; 58(2):155-160. PubMed ID: 28321094
[TBL] [Abstract][Full Text] [Related]
29. How I treat Waldenström macroglobulinemia.
Treon SP
Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
[TBL] [Abstract][Full Text] [Related]
30. Bing Neel Syndrome in a Previously Untreated Patient With Waldenström's Macroglobulinemia: Contribution of MYD88 L265P Mutation on Cerebrospinal Fluid.
Frustaci AM; Rusconi C; Picardi P; Veronese S; Montillo M; Cairoli R; Tedeschi A
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):e7-9. PubMed ID: 26705679
[No Abstract] [Full Text] [Related]
31. Significances of MYD88
Meng Q; Cao XX; Li J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):578-582. PubMed ID: 28877839
[TBL] [Abstract][Full Text] [Related]
32. [Waldenström's macroglobulinemia].
Poulain S; Wemeau M; Balkaran S; Hivert B; Hautecoeur A; Rossignol J; Fernandez J; Daudignon A; Roumier C; Soenen V; Lepelley P; Lai JL; Morel P; Leleu X
Rev Med Interne; 2010 May; 31(5):385-94. PubMed ID: 20363537
[TBL] [Abstract][Full Text] [Related]
33. Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction.
Jiménez C; Chillón Mdel C; Balanzategui A; Puig N; Sebastián E; Alcoceba M; Sarasquete ME; Conde IP; Corral R; Marín LA; Paiva B; Ruano M; Antón A; Maldonado R; San Miguel JF; González M; García-Sanz R
Appl Immunohistochem Mol Morphol; 2014; 22(10):768-73. PubMed ID: 24992174
[TBL] [Abstract][Full Text] [Related]
34. [Effective treatment with rituximab in two patients with Waldenström macroglobulinemia].
Yoshimi A; Arai S; Iijima K; Iki S; Usuki K; Urabe A
Rinsho Ketsueki; 2005 Oct; 46(10):1109-13. PubMed ID: 16440772
[TBL] [Abstract][Full Text] [Related]
35. Monitoring of MYD88 L265P mutation by droplet digital polymerase chain reaction for prediction of early relapse in a patient with Bing-Neel syndrome.
Shikata H; Kihara H; Kaneko M; Matsukage S; Hattori K
Int J Hematol; 2021 Apr; 113(4):586-591. PubMed ID: 33222046
[TBL] [Abstract][Full Text] [Related]
36. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
[TBL] [Abstract][Full Text] [Related]
37. Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia.
Garcia-Sanz R; Varettoni M; Jiménez C; Ferrero S; Poulain S; San-Miguel JF; Guerrera ML; Drandi D; Bagratuni T; McMaster M; Roccaro AM; Roos-Weil D; Leiba M; Li Y; Qiu L; Hou J; De Larrea CF; Castillo JJ; Dimopoulos M; Owen RG; Treon SP; Hunter ZR
Semin Hematol; 2023 Mar; 60(2):90-96. PubMed ID: 37099028
[TBL] [Abstract][Full Text] [Related]
38. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H
Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863
[TBL] [Abstract][Full Text] [Related]
39. MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.
Landgren O; Tageja N
Leukemia; 2014 Sep; 28(9):1799-803. PubMed ID: 24573383
[TBL] [Abstract][Full Text] [Related]
40. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2023 Feb; 98(2):348-358. PubMed ID: 36588395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
